| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
(E)-p-Coumaryl alcohol targets inflammatory pathways as it has been used for inflammation research. The compound exhibits significant cytotoxicity, suggesting activity against cell proliferation. As a coumarin metabolite, it may interact with enzymes involved in coumarin metabolism or inflammatory signaling pathways. Its antimicrobial and antioxidant properties indicate activity against microbial pathogens and reactive oxygen species. However, specific molecular targets have not been fully characterized in the published literature.
|
|---|---|
| ln Vitro |
In vitro, (E)-p-Coumaryl alcohol exhibits significant cytotoxicity. As a metabolite of coumarin, it may contribute to the biological activities of coumarin-containing plants. The compound has been isolated from Alpinia officinarum and Rhodiola rosea, plants known for their medicinal properties. It exhibits antioxidant, antimicrobial, and anti-inflammatory properties in various in vitro assays. However, detailed IC₅₀ values and specific activity data are not extensively published.
|
| ln Vivo |
In vivo activity data for (E)-p-Coumaryl alcohol are limited in the published literature. The compound has been primarily characterized through in vitro studies and as a natural product isolate. Given its anti-inflammatory properties, potential in vivo studies could include rodent models of inflammation. Its role as a coumarin metabolite suggests it may contribute to the in vivo effects of coumarin-containing plants. However, dedicated in vivo studies for this compound are not extensively published.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for (E)-p-Coumaryl alcohol are not extensively documented. Antioxidant activity can be evaluated using DPPH or ABTS radical scavenging assays. Antimicrobial activity is assessed using broth microdilution or disc diffusion methods against bacterial and fungal strains. Anti-inflammatory activity can be evaluated through inhibition of COX or LOX enzymes, or by measuring cytokine production in immune cells. The compound's structure can be confirmed by NMR and MS.
|
| Cell Assay |
In vitro cellular assays for (E)-p-Coumaryl alcohol typically involve evaluation of cytotoxicity in various cell lines. Cells are treated with serial dilutions of the compound and cell viability is assessed using MTT or similar assays. For anti-inflammatory studies, immune cells such as macrophages are treated with the compound and stimulated with LPS, and cytokine production is measured by ELISA. Antimicrobial activity is evaluated in bacterial or fungal culture systems.
|
| Animal Protocol |
In vivo animal experiments for (E)-p-Coumaryl alcohol have not been extensively reported. Based on its anti-inflammatory properties, potential studies could involve oral or intraperitoneal administration to rodent models of acute or chronic inflammation, with endpoints including inflammatory cytokine levels, tissue histopathology, and clinical signs. However, such studies have not been published for this specific compound to date.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (E)-p-Coumaryl alcohol are characteristic of phenylpropanoid compounds. The compound has a molecular weight of approximately 150.17 g/mol (calculated for C₉H₁₀O₂). As a small lipophilic molecule, it is expected to have good oral absorption and tissue distribution. It is a metabolite of coumarin, suggesting it is formed through metabolic transformation of coumarin in vivo. The compound is soluble in organic solvents and may have moderate water solubility due to the hydroxyl group.
|
| Toxicity/Toxicokinetics |
The toxicological profile of (E)-p-Coumaryl alcohol is not extensively documented. The compound exhibits significant cytotoxicity in vitro, indicating potential for cellular toxicity at higher concentrations. As a coumarin metabolite, its toxicity profile may be related to that of coumarin and other phenylpropanoid compounds. Comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
Trans-p-coumarol is a 4-hydroxycinnamicol with an E-configuration of the propenyl double bond. It is one of the major lignin monomers and possesses the functions of lignin monomers. It is a phenylpropanoid compound, belonging to the phenolic class, and is also a 4-hydroxycinnamicol. Functionally, it is related to (E)-cinnamicol. It has been reported that p-coumarol is present in potatoes (Solanum tuberosum), galangal (Alpinia officinarum), and several other organisms with relevant data. See also: Sodium lignosulfonate (monomer); Ammonium lignosulfonate (monomer); Calcium lignosulfonate (molecular weight 20000) (monomer)... See more...
(E)-p-Coumaryl alcohol (CAS# 20649-40-5), also known as (E)-p-Hydroxycinnamyl alcohol, is a coumarin metabolite isolated from Alpinia officinarum and Rhodiola rosea. It exhibits significant cytotoxicity and has been used in inflammation research. It also demonstrates antioxidant, antimicrobial, and anti-inflammatory properties. No clinical trials or regulatory approvals have been identified. |
| Molecular Formula |
C9H10O2
|
|---|---|
| Molecular Weight |
150.17
|
| Exact Mass |
150.068
|
| CAS # |
20649-40-5
|
| Related CAS # |
p-Coumaryl alcohol;3690-05-9
|
| PubChem CID |
5280535
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
213.5 °C
|
| Source |
Originated from plants: Zingiberaceae Alpinia officinarum Hance
|
| LogP |
1.397
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
124
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1/C=C/CO)O
|
| InChi Key |
PTNLHDGQWUGONS-OWOJBTEDSA-N
|
| InChi Code |
InChI=1S/C9H10O2/c10-7-1-2-8-3-5-9(11)6-4-8/h1-6,10-11H,7H2/b2-1+
|
| Chemical Name |
4-[(E)-3-hydroxyprop-1-enyl]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6591 mL | 33.2956 mL | 66.5912 mL | |
| 5 mM | 1.3318 mL | 6.6591 mL | 13.3182 mL | |
| 10 mM | 0.6659 mL | 3.3296 mL | 6.6591 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
